Abstract
ADC success requires that all three components of the agent function in a near-flawless manner. Equally important is that the target be selected with stringent consideration as the target is the one factor in ADC development that is immutable and beyond the reach of the developer to refine/manipulate. This chapter reviews the critical factors of target selection that must be met if one is to succeed at ADC development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and macromolecules in tumors. Cancer Res 50:814s–819s, PMID 2404582
Primeau AJ, Rendon A, Hedley D et al (2005) The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782–8788, PMID 16361566
Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927–936, PMID 2449118
Israeli RS, Powell CT, Fair WR et al (1994) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53:227–230, PMID 8417812
Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res 60:5237–5243, PMID 11016653
Israeli RS, Powell CT, Corr JG et al (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54:1807–1811, PMID 7511053
Sokoloff RL, Norton KC, Gasior CL et al (2000) A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 43:150–157, PMID 10754531
Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055–4060, PMID 9751609
Wright GL Jr, Haley C, Beckett ML et al (1995) Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol Oncol 1:18–28
Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552–558, PMID7665226
Wright GLJ, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334, PMID 8753752
Sweat SD, Pacelli A, Murphy GP et al (1998) PSMA expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640, PMID 8763054
Bostwick DG, Pacelli A, Blute M et al (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261, PMID 9610707
Mannweiler S, Amersdorfer P, Trajanoski S et al (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15(2):167–172, PMID 18802790
Kusumi T, Koie T, Tanaka M et al (2008) Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int 58:687–694, PMID 18844933
Ananias HJ, van den Heuvel MC, Helfrich W et al (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69:1101–1108, PMID 19343734
Liu H, Moy P, Kim S et al (1997) Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629–3634, PMID 9288760
Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85, PMID 9815541
Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192–3198, PMID 10397265
Chang SS, O’Keefe DS, Bacich DJ et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681, PMID 10537328
Al-Ahmadie HA, Olgac S, Gregor PD et al (2008) Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 21:727–732, PMID 18344976
Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586–592, PMID 20357763
Haffner MC, Kronberger IE, Ross JS et al (2009) Prostate specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40:1754–1761, PMID 19716160
Kuroda K, Liu H, Li M et al. Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability. Manusc Submitted
Evans MJ, Smith-Jones PM, Wongvipat J et al (2011) Non-invasive measurement of androgen receptor signaling with 64Cu-J591, a positron emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 108:9578–9582
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Bander, N.H. (2013). Antibody–Drug Conjugate Target Selection: Critical Factors. In: Ducry, L. (eds) Antibody-Drug Conjugates. Methods in Molecular Biology, vol 1045. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-541-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-62703-541-5_2
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-540-8
Online ISBN: 978-1-62703-541-5
eBook Packages: Springer Protocols